Cardiol Therapeutics Inc. (CRDL.TO) TSX
Currency In CAD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CAD
Address
2265 Upper Middle Road East
Oakville, ON L6H 0G5
Canada
Phone
289 910 0850
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
18
First IPO Date
December 20, 2018
| Name | Title | Pay | Year Born |
| David G. Elsley | President, Chief Executive Officer & Director | 774,400 | N/A |
| Christopher J. Waddick | Chief Financial Officer, Corporate Secretary & Director | 303,600 | N/A |
| Bernard Lim | Chief Operating Officer | 531,300 | N/A |
| Andrew Warwick Hamer | Chief Medical Officer and Head of Research & Development | 801,662 | 1962 |
| John A. Geddes BSCPT | Vice President of Corporate Development | 0 | N/A |
| Trevor Burns | Investor Relations | 0 | N/A |
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.